Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines.
Immunomic Therapeutics has raised $6.5M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in June 2025.
Immunomic Therapeutics's investors include Life Sciences Greenhouse of Pennsylvania, Brainchild Holdings, Keiretsu Forum Northwest, Mid Atlantic Bio Angels, Minority Angel Investor Network.
Immunomic Therapeutics is headquartered in Lancaster, United States.
Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines.
Immunomic Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Immunomic Therapeutics — Funding & Investors." VCBacked, June 2, 2025, https://www.vcbacked.co/company/immunomic-therapeutics. Accessed July 20, 2026.
VCBacked. (2025). Immunomic Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/immunomic-therapeutics
{{cite web |title=Immunomic Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/immunomic-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated